Resources Repository
-
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Cost-Effectiveness Analysis | Decision Analysis | Economics/Finance | Europe | North America | Chronic Disease/Risk | Preferences/Values | Health Outcomes | Health Systems | Health/Medicine -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Cost-Effectiveness Analysis | Economics/Finance | North America | Global | Chronic Disease/Risk | Test Performance | State-Transition | Microsimulation | Infectious Diseases | Health Systems | Health/Medicine -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Cost-Effectiveness Analysis | Economics/Finance | Global | Chronic Disease/Risk | Mental Health | Priority Setting/Ethics | Benefit-Cost Analysis | Infectious Diseases | Health Systems | Health/Medicine -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Cost-Effectiveness Analysis | Decision Analysis | Economics/Finance | Global | Chronic Disease/Risk | Mathematical Models | Infectious Diseases | Health/Medicine | Science/Technology -
ArticlePublication 2022Health and Financial Risk Protection Outcomes in Economic Evaluations
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution …
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution of health gains and financial risk protection. This information is typically presented in a joint display format. This article develops and applies an algebraic money-metric formulation that incorporates all disaggregated outcomes and finds that ranking of health interventions is sensitive to the decision maker’s aversion to inequality across income groups and that financial risk protection gains are most important to…
Cost-Effectiveness Analysis | Economics/Finance | Global | Chronic Disease/Risk | Priority Setting/Ethics | Social Determinants | Health/Medicine -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Cost-Effectiveness Analysis | Economics/Finance | Global | Chronic Disease/Risk | Costing Methods | Evidence Synthesis | Infectious Diseases | Health Systems | Health/Medicine -
ArticlePublication 2013Nutritional Policy Changes in SNAP: A Microsimulation and Cost-Effectiveness Analysis
This analysis estimated the health effects and cost-effectiveness of banning or taxing sugar-sweetened beverages (SSBs) …
This analysis estimated the health effects and cost-effectiveness of banning or taxing sugar-sweetened beverages (SSBs) or subsidizing fruits and vegetables purchased with SNAP. The target population was adults in the U.S. and the time horizon was 10 years. Results showed that banning SSB purchases using SNAP benefits would be expected to avert 510,000 diabetes person-years and 52,000 deaths from MIs and strokes over the next decade, with a savings of $2900 per QALY saved. A…
Cost-Effectiveness Analysis | Economics/Finance | North America | Chronic Disease/Risk | Mathematical Models | Microsimulation | Policy/Regulation | Food/Agriculture | Government/Law | Health/Medicine -
ArticlePublication 2019Cost-Effectiveness of U.S. National SSB Tax with a Multistakeholder Approach: Who Pays and Who Benefits
This analysis estimated the health impact and cost-effectiveness of a national penny-per-ounce sugar-sweetened beverage (SSB) …
This analysis estimated the health impact and cost-effectiveness of a national penny-per-ounce sugar-sweetened beverage (SSB) tax, overall and with stratified costs and benefits for nine distinct stakeholder groups. A microsimulation model (CVD PREDICT) was used to estimate cardiovascular disease reductions, quality-adjusted life years gained, and cost-effectiveness for U.S. adults aged 35 to 85 years, evaluating full and partial consumer price pass-through. Results showed that from both a health care and societal perspective, the SSB tax was…
Cost-Effectiveness Analysis | Economics/Finance | North America | Chronic Disease/Risk | Microsimulation | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine -
ArticlePublication 2019Health Impact and Cost-Effectiveness of SSB Taxes for Reducing Cancer Burden in the U.S.
This analysis evaluated the health outcomes, costs, and cost-effectiveness of a national sugar-sweetened beverage (SSB) …
This analysis evaluated the health outcomes, costs, and cost-effectiveness of a national sugar-sweetened beverage (SSB) tax policy for reducing obesity-related cancer in the U.S. A probabilistic cohort state-transition model, the Diet Cancer Outcome Model (DiCOM), was used to project the effect of a national $0.01 per ounce SSB excise tax on 13 obesity-associated cancers among U.S. adults age 20 and older over their lifetime. Cost-effectiveness was evaluated using both government affordability and societal perspectives. Results showed…
Cost-Effectiveness Analysis | Economics/Finance | North America | Chronic Disease/Risk | Mathematical Models | Microsimulation | Policy/Regulation | Government/Law | Health/Medicine